More convenient proteasome inhibition for improved outcomes
Mené sur 578 patients atteints d'un myélome multiple récidivant ou réfractaire, cet essai de phase III compare l'efficacité, du point de vue de la survie sans progression, et la toxicité du carfilzomib, un inhibiteur sélectif du protéasome, dispensé une fois (70 mg/m2) ou deux fois (27 mg/m2) par semaine
The development of proteasome inhibitors for the treatment of multiple myeloma has represented a step-change for patients with this incurable plasma cell cancer, bringing increased treatment responses, and improved survival. Gradual familiarisation with toxicity profiles, and optimisation of dosing schedules, have shaped the current use of proteasome inhibitors as key components of several treatment regimens. The first-in-class proteasome inhibitor bortezomib was approved in 2003 for relapsed and subsequently also for newly diagnosed multiple myeloma.
The Lancet Oncology , commentaire, 2017